Circassia Establishes Commercial-Scale Supply Chain
Circassia to Develop Dopexamine as Part of Proprietary Post-Surgery
OXFORD, England, Oct. 8 /CNW/ - Circassia Ltd, a specialty
biopharmaceutical company focused on the fields of allergy and critical care,
announced today that it has acquired the US, Canadian and Japanese development
and commercialization rights to dopexamine from the international speciality
pharmaceutical company Ipsen. Circassia has also entered into agreements with
pharmaceutical manufacturers Excella and Hospira to establish a
commercial-scale supply chain for the product.
Circassia is developing dopexamine in a new indication as an integral
part of proprietary structured protocols designed to dramatically improve
patient recovery following a range of high-risk surgeries. This novel
approach, named ToleroCare(R), which Circassia has recently patented, combines
the use of dopexamine with the administration of intra-venous fluids to
improve tissue oxygenation levels during the recovery period after surgery.
The precise use of fluids and dopexamine is based on carefully defined
parameters such as heart stroke volume and oxygen delivery index.
ToleroCare therapy has already achieved clinical proof-of-concept in a
phase II single-blind, randomized, controlled trial in 122 high-risk general
surgery patients in the UK. The study showed that significantly fewer patients
who received ToleroCare experienced complications in the 30 day period
following surgery compared with those on standard treatment (44% vs. 68%; p =
0.003). In addition, ToleroCare patients recovered significantly quicker,
staying in hospital for 17.5 days on average compared with 29.5 days (p =
0.001) for those who received standard therapy.
Dopexamine is a beta2 adrenoceptor and dopamine receptor agonist, which
is approved in Europe in indications related to heart failure. Dopexamine is
not approved for use currently in the US, Canada or Japan.
"ToleroCare has great potential to dramatically improve patients'
recovery following major surgery, as well as to significantly reduce costs by
shortening the time spent in hospital. With approximately 825,000 high-risk
surgical procedures carried out each year in the US, and the high cost
associated with hospital stays, ToleroCare is targeting a major market
opportunity," said Steve Harris, Circassia's CEO. "Dopexamine provides
Circassia with a further phase II clinical-stage development programme that
fits well with our outsourced business model. By establishing a
commercial-scale supply chain for dopexamine, we are well positioned to
rapidly progress ToleroCare to market."
Circassia is a specialty biopharmaceutical company focused on the fields
of allergy and critical care. The company has a highly experienced management
team with a proven track record in product development and commercialization,
and having successfully completed two fundraising rounds is backed by a
syndicate of world-class venture capital and institutional investors, which
includes Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco
Circassia's lead products target allergies utilizing the company's
proprietary T-cell epitope desensitization technology, ToleroMune(R). The
company is also developing its ToleroTrans(R) organ anti-rejection technology,
which uses a similar approach to down-regulate immune responses in transplant
patients. Circassia has a number of ongoing development programmes, with the
most advanced against cat-dander allergy in phase II clinical testing.
For more information please visit http://www.circassia.co.uk.
For further information:
For further information: Steve Harris, CEO, Circassia, Tel:
+44(0)1865-784574; Rob Budge, RJB Communications, Tel: +44(0)1865-760969,